The company's File Number is listed as 001319330.
As of 07/02/2020 . A change to a single letter, known as a point mutation, can mean the difference between health and disease. Beam Therapeutics Inc. is a Massachusetts Foreign Corporation filed on March 23, 2018. If existing gene editing approaches are like “scissors” that cut the genome, base editors are “pencils” that enable erasing and rewriting one letter of the genome at a time.Our team and culture are central to building an organization that we are all proud of and one that will allow us to realize our vision of providing life-long cures for patients suffering from serious diseases. We have attracted a talented team of industry experts and scientists as part of our high performing team. ... Health Care. March 18, 2020 Scientist I/II, In Vivo Liver Biology.
By using base editors to rewrite a single letter of the genome, Beam has the potential to create life-long cures for patients suffering from serious diseases. Beam Therapeutics serves customers in the State of Massachusetts. BEAM:US 28.87 USD +0.36 +1.26%. FOUNDED.
26 Landsdowne Street 2nd Floor Cambridge, MA 02139 info@beamtx.com We are currently seeking a self-motivated and technically competent scientist to join our team. The Registered Agent on file for this company is C T Corporation System and is located at 155 Federal St., Suite 700, Boston, MA 02110.
Biotech & Pharma. Base editors can be used for numerous therapeutic applications to treat disease. They can be used to correct disease-causing point mutations, to modify genes to create protective genetic variations, to activate or silence gene expression, or “multiplex” by making multiple simultaneous base edits. SEE QUOTE.
He/She will support our exploratory research Read More. The company's principal address is 675 W. Kendall St., Cambridge, MA 02142. SUB-INDUSTRY. Using this toolkit of approaches, we are advancing a broad, diversified portfolio of 12 base editing programs against distinct editing targets and diseases.We are continuing to build a strong, values-driven organization focused on our people, advancing cutting-edge science, and rigorously developing a new class of precision genetic medicines. INDUSTRY.
Biotech. Beam Therapeutics is seeking a highly talented and motivated Head of Chemistry with expertise in oligo synthesis, nucleic acids and Read More. Our depth of expertise in base editing and drug discovery, along with the considerable academic and research expertise of our founders and our exclusive licenses to novel technologies, positions us at the forefront of the field of advanced precision genetic medicines.– MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia – CAMBRIDGE, Mass. Our culture is an essential component to maintaining our competitive long-term advantage.The foundational level of our genetic information is a single base in our DNA. 01/25/2017. … Base editors have the ability to rewrite just a single letter, and thereby intervene at the most foundational level to treat a wide range of diseases. ADDRESS…
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. SECTOR. Get in touch with us. CURRENT PRICE.
--(BUSINESS WIRE)--Jun.
Beam Therapeutics serves customers in the State of Massachusetts.